← Daiichi Sankyo Company overview

Daiichi Sankyo Company vs China Resources Double-Crane Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Daiichi Sankyo Company, Limited (4568.JP)

Q3 2026
▲3▼1

Daiichi Sankyo's ADC Franchise Expands with EU Approvals and Strong Revenue

  • EU Approvals for Datroway and Enhertu Datroway received EU first-line TNBC approval, while Enhertu gained EU tumor-agnostic approval, triggering a $25M AstraZeneca milestone. These expand treatment options and validate the ADC platform.

    These approvals are major regulatory wins that open new markets and drive revenue potential.

  • Enhertu Reimbursement and Trial Success Enhertu secured NHS England reimbursement for HER2-low breast cancer after earlier rejection and showed strong first-line lung cancer data. This improves patient access and supports future growth.

    Reimbursement and positive trial results directly impact sales and market confidence.

  • Strong Q1 Revenue and Raised Guidance Q1 revenue jumped 21% to ¥574.7B, prompting raised full-year guidance. This reflects robust business performance and management confidence.

    Revenue growth and guidance raise are key financial indicators that drive investor sentiment.

  • Reimbursement Uncertainty and Undisclosed Economics The NHS pricing deal could still fall through, and confidential discounts obscure the exact financial benefit of expanded access. These factors temper the positive outlook.

    These risks could limit the financial upside from approvals and reimbursements.

August 2026
▲4

Daiichi Sankyo's cancer drugs win approvals, trials and NHS access

  • Datroway approved in EU for first-line TNBC Datroway became the first TROP2 antibody-drug conjugate approved in the EU for first-line triple-negative breast cancer, with a 5-month overall survival benefit. This opens a new, large market and supports the drug's rapid sales growth, pushing 4568.JP up.

    New approval directly expands the commercial opportunity for a key growth drug.

  • Full-year guidance raised on 21% revenue jump First-quarter revenue rose 21% to 574.7 billion yen, led by Enhertu and Datroway, and management raised full-year revenue and profit forecasts. Stronger U.S. sales and favorable currency rates underpin the upgrade, boosting investor confidence in 4568.JP.

    Guidance raise signals stronger-than-expected business momentum and earnings power.

  • Enhertu shows strong first-line lung cancer data Enhertu cut the risk of progression or death by 37% versus standard care in first-line HER2-mutant lung cancer, with median progression-free survival of 14.3 months. Positive phase 3 results raise the chance of expanded approval, adding to 4568.JP's long-term growth outlook.

    Late-stage trial success increases the probability of a new major indication for Enhertu.

  • NHS England reimburses Enhertu for HER2-low breast cancer England's NHS reversed an earlier rejection and will fund Enhertu for about 1,000 women a year with HER2-low metastatic breast cancer. As co-developer, Daiichi Sankyo shares in the expanded access, though confidential discounts mean the exact financial benefit is unclear.

    Reimbursement win widens patient access and commercial reach for a core drug.

Latest
▲4

Daiichi Sankyo's cancer drugs win approvals, trials and NHS access

  • Datroway approved in EU for first-line TNBC Datroway became the first TROP2 antibody-drug conjugate approved in the EU for first-line triple-negative breast cancer, with a 5-month overall survival benefit. This opens a new, large market and supports the drug's rapid sales growth, pushing 4568.JP up.

    New approval directly expands the commercial opportunity for a key growth drug.

  • Full-year guidance raised on 21% revenue jump First-quarter revenue rose 21% to 574.7 billion yen, led by Enhertu and Datroway, and management raised full-year revenue and profit forecasts. Stronger U.S. sales and favorable currency rates underpin the upgrade, boosting investor confidence in 4568.JP.

    Guidance raise signals stronger-than-expected business momentum and earnings power.

  • Enhertu shows strong first-line lung cancer data Enhertu cut the risk of progression or death by 37% versus standard care in first-line HER2-mutant lung cancer, with median progression-free survival of 14.3 months. Positive phase 3 results raise the chance of expanded approval, adding to 4568.JP's long-term growth outlook.

    Late-stage trial success increases the probability of a new major indication for Enhertu.

  • NHS England reimburses Enhertu for HER2-low breast cancer England's NHS reversed an earlier rejection and will fund Enhertu for about 1,000 women a year with HER2-low metastatic breast cancer. As co-developer, Daiichi Sankyo shares in the expanded access, though confidential discounts mean the exact financial benefit is unclear.

    Reimbursement win widens patient access and commercial reach for a core drug.

July 2026
▲4

Daiichi Sankyo's ADC Franchise Expands with EU Approvals and NHS Pricing Deal

  • Datroway EU First-Line TNBC Recommendation Datroway, a TROP2 antibody-drug conjugate, was recommended for EU approval as first-line treatment for metastatic triple-negative breast cancer. The trial showed a 5-month overall survival benefit and 43% reduction in disease progression risk. This opens a new market and boosts future revenue potential.

    New regulatory milestone directly expands Daiichi Sankyo's oncology portfolio and revenue outlook.

  • Enhertu EU Tumor-Agnostic Approval and Milestone Enhertu became the first tumor-agnostic HER2-directed ADC approved in the EU, triggering a $25 million milestone payment from AstraZeneca. This broadens Enhertu's label to many cancer types, increasing its patient population and long-term sales potential.

    New approval and immediate cash milestone reinforce Enhertu's blockbuster status and Daiichi Sankyo's earnings.

  • NHS Pricing Deal for Enhertu Nears AstraZeneca and Daiichi Sankyo are close to a pricing agreement with NHS England for Enhertu, which could make the drug available to nearly 1,000 women with breast cancer. A deal would expand access and add revenue, though it could still fall through.

    New pricing agreement would unlock a major market and signal broader reimbursement momentum.

  • Enhertu Plus Pertuzumab EU First-Line Recommendation The EMA recommended Enhertu plus pertuzumab as first-line treatment for HER2-positive metastatic breast cancer, with a 44% reduction in progression risk and 40.7-month median progression-free survival. If approved, it would be the first new first-line option in over a decade.

    New combination therapy recommendation expands Enhertu's use earlier in treatment, driving higher sales.

▲4

Daiichi Sankyo's ADC Franchise Expands with EU Approvals and NHS Pricing Deal

  • Datroway EU First-Line TNBC Recommendation Datroway, a TROP2 antibody-drug conjugate, was recommended for EU approval as first-line treatment for metastatic triple-negative breast cancer. The trial showed a 5-month overall survival benefit and 43% reduction in disease progression risk. This opens a new market and boosts future revenue potential.

    New regulatory milestone directly expands Daiichi Sankyo's oncology portfolio and revenue outlook.

  • Enhertu EU Tumor-Agnostic Approval and Milestone Enhertu became the first tumor-agnostic HER2-directed ADC approved in the EU, triggering a $25 million milestone payment from AstraZeneca. This broadens Enhertu's label to many cancer types, increasing its patient population and long-term sales potential.

    New approval and immediate cash milestone reinforce Enhertu's blockbuster status and Daiichi Sankyo's earnings.

  • NHS Pricing Deal for Enhertu Nears AstraZeneca and Daiichi Sankyo are close to a pricing agreement with NHS England for Enhertu, which could make the drug available to nearly 1,000 women with breast cancer. A deal would expand access and add revenue, though it could still fall through.

    New pricing agreement would unlock a major market and signal broader reimbursement momentum.

  • Enhertu Plus Pertuzumab EU First-Line Recommendation The EMA recommended Enhertu plus pertuzumab as first-line treatment for HER2-positive metastatic breast cancer, with a 44% reduction in progression risk and 40.7-month median progression-free survival. If approved, it would be the first new first-line option in over a decade.

    New combination therapy recommendation expands Enhertu's use earlier in treatment, driving higher sales.

China Resources Double-Crane Pharmaceutical Co Ltd (600062.CG)

Q3 2026
▲3▼1

Double-Crane bets on Lier Chemical while earnings slip and drug pipeline grows

  • 5.66 billion yuan Lier Chemical acquisition Double-Crane won the bid to buy 23.5% of Lier Chemical for 5.656 billion yuan cash, becoming its controlling shareholder. This expands into pesticides and synthetic biology, a long-term growth bet, though it uses a lot of cash and is a major restructuring.

    This is the biggest new event of the period and the main force behind the stock's story.

  • Interim profit and revenue fall First-half 2026 net profit was 946 million yuan, down 3.43%, and revenue fell 3.44% to 5.615 billion yuan. This shows the core business is under pressure, a real counterweight to the acquisition and pipeline news.

    It is the key financial result of the period and the main negative force on the stock.

  • New drug approvals and trial progress The company completed a Phase III trial for pregabalin extended-release tablets and received approvals for acetazolamide capsules, sodium lactate Ringer's irrigation solution, lomustine capsules, and ezetimibe/atorvastatin tablets. These add future revenue sources.

    A steady stream of pipeline wins supports long-term growth even as current earnings dip.

  • Dividend and procurement selection Double-Crane paid a cash dividend of 3.79 yuan per 10 shares and had products proposed for selection in the 12th national centralized drug procurement. Both are shareholder-friendly and support sales volume, though price cuts from procurement can pressure margins.

    These are new capital-return and demand-side events that affect investor income and product demand.

August 2026
▲3▼1

Double-Crane bets on Lier Chemical while earnings slip and drug pipeline grows

  • 5.66 billion yuan Lier Chemical acquisition Double-Crane won the bid to buy 23.5% of Lier Chemical for 5.656 billion yuan cash, becoming its controlling shareholder. This expands into pesticides and synthetic biology, a long-term growth bet, though it uses a lot of cash and is a major restructuring.

    This is the biggest new event of the period and the main force behind the stock's story.

  • Interim profit and revenue fall First-half 2026 net profit was 946 million yuan, down 3.43%, and revenue fell 3.44% to 5.615 billion yuan. This shows the core business is under pressure, a real counterweight to the acquisition and pipeline news.

    It is the key financial result of the period and the main negative force on the stock.

  • New drug approvals and trial progress The company completed a Phase III trial for pregabalin extended-release tablets and received approvals for acetazolamide capsules, sodium lactate Ringer's irrigation solution, lomustine capsules, and ezetimibe/atorvastatin tablets. These add future revenue sources.

    A steady stream of pipeline wins supports long-term growth even as current earnings dip.

  • Dividend and procurement selection Double-Crane paid a cash dividend of 3.79 yuan per 10 shares and had products proposed for selection in the 12th national centralized drug procurement. Both are shareholder-friendly and support sales volume, though price cuts from procurement can pressure margins.

    These are new capital-return and demand-side events that affect investor income and product demand.

Latest
▲3▼1

Double-Crane bets on Lier Chemical while earnings slip and drug pipeline grows

  • 5.66 billion yuan Lier Chemical acquisition Double-Crane won the bid to buy 23.5% of Lier Chemical for 5.656 billion yuan cash, becoming its controlling shareholder. This expands into pesticides and synthetic biology, a long-term growth bet, though it uses a lot of cash and is a major restructuring.

    This is the biggest new event of the period and the main force behind the stock's story.

  • Interim profit and revenue fall First-half 2026 net profit was 946 million yuan, down 3.43%, and revenue fell 3.44% to 5.615 billion yuan. This shows the core business is under pressure, a real counterweight to the acquisition and pipeline news.

    It is the key financial result of the period and the main negative force on the stock.

  • New drug approvals and trial progress The company completed a Phase III trial for pregabalin extended-release tablets and received approvals for acetazolamide capsules, sodium lactate Ringer's irrigation solution, lomustine capsules, and ezetimibe/atorvastatin tablets. These add future revenue sources.

    A steady stream of pipeline wins supports long-term growth even as current earnings dip.

  • Dividend and procurement selection Double-Crane paid a cash dividend of 3.79 yuan per 10 shares and had products proposed for selection in the 12th national centralized drug procurement. Both are shareholder-friendly and support sales volume, though price cuts from procurement can pressure margins.

    These are new capital-return and demand-side events that affect investor income and product demand.